Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors
Conditions
Interventions
PRT2527
Locations
8
United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Investigational Drug Services, AdventHealth Celebration
Celebration, Florida, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Start Date
February 14, 2022
Primary Completion Date
December 6, 2023
Completion Date
December 6, 2023
Last Updated
December 11, 2023
NCT07548177
NCT07467772
NCT05969860
NCT04693377
NCT04308330
NCT07308886
Lead Sponsor
Prelude Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions